Streptococcus pneumoniae serotype 38 emerges as one of the dominant serotypes causing invasive pneumococcal disease in Germany and Poland, but not in the Netherlands

Streptococcus pneumoniae is a major cause of community-acquired pneumonia and invasive diseases. Vaccination prevents pneumococcal disease caused by vaccine serotypes but leads to an increase in disease caused by non-vaccine serotypes. We aimed to characterise serotype 38 isolates from invasive pneu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of infection Jg. 91; H. 1; S. 106519
Hauptverfasser: Hajji, Karim, Wróbel-Pawelczyk, Izabela, van Veldhuizen, Janieke, Maruhn, Karsten, Miellet, Willem R., Mariman, Rob, Steens, Anneke, van Sorge, Nina M., Trzciński, Krzysztof, van der Linden, Mark P.G., Skoczyńska, Anna, Visser, Linda J.
Format: Journal Article
Sprache:Englisch
Veröffentlicht: England Elsevier Ltd 01.07.2025
Schlagworte:
Adolescent
Adult
Aged
Aged, 80 and over
Anti-Bacterial Agents - pharmacology
Child
Child, Preschool
Drug Resistance, Bacterial
Epidemiology
Female
Germany - epidemiology
Humans
Incidence
Infant
Infant, Newborn
Infectious Disease
Invasive pneumococcal disease
Male
Microbial Sensitivity Tests
Middle Aged
Netherlands - epidemiology
Phylogeny
Pneumococcal Infections - epidemiology
Pneumococcal Infections - microbiology
Poland - epidemiology
Serogroup
Serotype 38
Streptococcus pneumoniae
Streptococcus pneumoniae - classification
Streptococcus pneumoniae - drug effects
Streptococcus pneumoniae - genetics
Streptococcus pneumoniae - isolation & purification
Surveillance
Vaccine preventable diseases
Young Adult
Poland
Netherlands
Germany
Vaccine preventable diseases
Invasive pneumococcal disease
Surveillance
Epidemiology
Serotype 38
Streptococcus pneumoniae
ISSN:0163-4453, 1532-2742, 1532-2742
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Streptococcus pneumoniae is a major cause of community-acquired pneumonia and invasive diseases. Vaccination prevents pneumococcal disease caused by vaccine serotypes but leads to an increase in disease caused by non-vaccine serotypes. We aimed to characterise serotype 38 isolates from invasive pneumococcal disease (IPD) patients in Germany, Poland and the Netherlands to explain a recent surge in cases. IPD surveillance data from 2013/2014 to 2023/2024 were reviewed in all three countries for trends in serotype 38 incidence. Collected isolates were serotyped and phenotypically tested for antimicrobial resistance. Selected serotype 38 isolates (n=130) were sequenced and subjected to phylogenetic analysis, along with 213 publicly available genomes, and characterised according to their virulence and resistance genes. Surveillance data revealed an increase in the percentage of serotype 38 in IPD in Germany and Poland in 2023/2024. This was most pronounced among children aged 0–4 years (from 4.3% to 17.1% and 4.0% to 15.8% of IPD cases, respectively) and adults aged ≥60 years (from 1.5% to 7.0% and from 0.7% to 2.9%, respectively). No such rise in serotype 38 IPD was observed in the Netherlands. Phylogenetic analysis showed that recent isolates mostly emerged from previously circulating strains, showed no significant changes in gene content and carried little antimicrobial resistance genes. The recent surge in non-vaccine serotype 38 among IPD cases in Germany and Poland cannot be explained by changes in antimicrobial resistance or other genetic changes. Our study underscores the importance of international collaboration in monitoring pneumococcal serotype trends to inform policymakers. •Serotype 38 pneumococcus is becoming a top non-vaccine type in invasive disease.•This increased incidence makes serotype 38 a potential vaccine candidate.•Recent isolates emerged from previously circulating strains.•No new virulence or AMR characteristics can explain the rise.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0163-4453
1532-2742
1532-2742
DOI:10.1016/j.jinf.2025.106519